Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

George Pentheroudakis,Vassiliki Kotoula,Wendy De Roock,George Kouvatseas,Pavlos Papakostas,Thomas Makatsoris,Demetris Papamichael,Ioannis Xanthakis,Joseph Sgouros,Despina Televantou,Georgia Kafiri,Athanassios C. Tsamandas,Evangelia Razis,Eleni Galani,Dimitrios Bafaloukos,Ioannis Efstratiou,Iliada Bompolaki,Dimitrios Pectasides,Nicholas Pavlidis,Sabine Tejpar,George Fountzilas

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

2013

Background More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy.

Keywords:

Cancer research
Cetuximab
Epidermal growth factor
Pathology
Colorectal cancer
Epidermal growth factor receptor
Biomarker (medicine)
KRAS
Monoclonal antibody
Medicine
Adenocarcinoma
Monoclonal

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations